Browse drugs

… months (erenumab), 12.9 months (fremanezumab) and 19.0 months (galcanezumab). Mean MDM reduction was: galcanezumab –7.3 days/month (p<0.000…

…epant: 5 changed from erenumab, 2 from galcanezumab, and 1 from galcanezumab. There were 11 line changes to eptinezumab: 5 from erenumab, 4 …

…9% male; 64.6% received fremanezumab, 24.8% erenumab, 10.6% and galcanezumab; 75.7% were on first-line therapy, 21.7% second-line and 2.7% t…

…as 85.4% for galcanezumab, 81.3% for fremanezumab and 84.2% for erenumab; at 4 years it was 69.2%, 73.5% and 63.9% respectively. Among 6…

…ed in 81% (N=13) of treatments: 2 atogepant, 1 erenumab, and 10 fremanezumab. A mean of 11 MMDs and 52 HIT6 score were recorded at beginning…

…e preventive treatment after lack of efficacy or intolerance to galcanezumab.Material and Methods A retrospective observational study was co…

…frequent for erenumab (31%), followed by galcanezumab (27%) and eptinezumab (15%).Conclusion and Relevance Treatment effectiveness was obse…

…mab, 44.4% (55) fremanezumab, 15.3% (19) erenumab, and 2.4% (3) eptinezumab.First cycle efficacy: The median baseline MMD was 12 (10–15.5),…

…he following CGRP pathway-targeted preventive treatments: 32.4% galcanezumab, 28.1% erenumab, 24.3% fremanezumab, 8.2% atogepant, 2.5% eptin…

…lonal antibody, 23 (41,8%) with galcanezumab and 7 (12,7%) with erenumab.At the end of the follow-up 39 (70,9%) patients had discontinue…

…remenezumab and galcanezumab. Conclusion Our findings show that eptinezumab is a safe, well-tolerated migraine prophylactic that decreases …

…ated lesions after denervation in rats.50 β-blockers (including propranolol and propranolol hydrochloride), which target adrenergic nerves,…